<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Low-Dose Aspirin: The Safest Prophylactic Approach for Venous Thromboembolism Prevention Following Total Hip Arthroplasty Across All Risk Profiles

dc.contributor.authorPorto, Joshua R.
dc.contributor.authorLavu, Monish S.
dc.contributor.authorHecht, Christian J., II
dc.contributor.authorArnold, Keith E.
dc.contributor.authorAcuna, Alexander J.
dc.contributor.authorKaelber, David C.
dc.contributor.authorParvizi, Javad
dc.contributor.authorKamath, Atul F.
dc.date.accessioned2026-11-05T11:07:05Z
dc.date.issued2026
dc.description.abstractBackground Venous thromboembolism (VTE) remains a major concern following total hip arthroplasty (THA). While multiple agents are used for chemoprophylaxis, the 2022 International Consensus Meeting (ICM) on VTE endorsed low-dose aspirin as the preferred option for all THA patients. However, data comparing aspirin with other anticoagulants across different VTE risk profiles remain limited. Methods This retrospective cohort study analyzed patients undergoing primary THA between 2012 and 2023 using a large national database. Patients were stratified into VTE high-risk and low-risk groups based on ICM criteria and comorbidities identified in prior national analyses. Chemoprophylactic regimens included low-dose aspirin (81 mg) and other anticoagulants; patients receiving high-dose aspirin were excluded. Among 147,437 THA patients, use of low-dose aspirin increased from 0.4% in 2012 to 60.9% in 2023. Outcomes included 90-day rates of deep vein thrombosis, pulmonary embolism, hemorrhage, hematoma, gastrointestinal bleeding, infection, myocardial infarction, stroke, mortality, revision, emergency department visits, and readmissions. Propensity score matching (1:1) was applied to control for demographic and clinical variables. Statistical significance was defined as P < 0.05. Results In both high- and low-risk groups, aspirin-only prophylaxis was associated with lower odds of deep vein thrombosis (odds ratio (OR): 0.29 high-risk, 0.16 low-risk), pulmonary embolism (OR: 0.32 to 0.25), hemorrhage (OR: 0.13 to 0.09), gastrointestinal bleeding (OR: 0.42 to 0.27), and mortality (OR: 0.33 to 0.48) compared to alternative agents. Conclusions Low-dose aspirin was associated with significantly lower rates of thromboembolic, bleeding, and mortality outcomes in both high- and low-risk THA patients. These findings support the ICM recommendation of aspirin as a safe, effective, and broadly applicable thromboprophylaxis strategy following THA. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
dc.description.issue5
dc.description.pages1525-1532
dc.description.sponsorshipThis project was supported by the Clinical and Translational Science Collaborative of Cleveland which is funded by the National Institutes of Health, National Center for Advancing Translational Science, Clinical and Translational Science Award grant, UL1TR002548. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
dc.description.volume41
dc.identifier.doi10.1016/j.arth.2025.09.026
dc.identifier.issn0883-5403
dc.identifier.issn1532-8406
dc.identifier.urihttps://doi.org/10.1016/j.arth.2025.09.026
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11417
dc.identifier.wosWOS:001745669300001
dc.language.isoen
dc.publisherCHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
dc.relation.fundingClinical and Translational Science Collaborative of Cleveland - National Institutes of Health, National Center for Advancing Translational Science, Clinical and Translational Science Award grant
dc.relation.fundingClinical and Translational Science Collaborative of Cleveland - National Institutes of Health, National Center for Advancing Translational Science, Clinical and Translational Science Award grant [UL1TR002548]
dc.relation.hasversion10.1016/j.arth.2025.09.026
dc.relation.ispartofJOURNAL OF ARTHROPLASTY
dc.subjecttotal hip arthroplasty
dc.subjectvenous thromboembolism
dc.subjectlow-dose aspirin
dc.subjectthromboprophylaxis
dc.subjectanticoagulation
dc.subjectMOLECULAR-WEIGHT HEPARIN
dc.subjectPULMONARY-EMBOLISM
dc.subjectOrthopedics
dc.titleLow-Dose Aspirin: The Safest Prophylactic Approach for Venous Thromboembolism Prevention Following Total Hip Arthroplasty Across All Risk Profiles
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.endPage1532
oaire.citation.issue5
oaire.citation.startPage1525
oaire.citation.volume41
person.identifier.ridAAJ-5963-2021

Files

Collections